NEW YORK--(BUSINESS WIRE)--Jan. 31, 2006--Axonyx Inc. (NASDAQ: AXYX) announced today that three presentations of data on its drug development candidate, Phenserine, and one presentation of data on its drug development candidate, Posiphen(TM), will be made at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy in Geneva, Switzerland, being held April 19-22, 2006. Phenserine has been in development by the Company for the treatment of mild to moderate Alzheimer’s disease (AD) and Posiphen is currently being developed for the treatment of AD progression.
